title: [Clinical evaluation of calculating carboplatin dosage using Japanese equation for estimating GFR for gynecologic cancer].
abstract: Glomerular filtration rate (GFR) is an important factor when considering carboplatin dosage adjustment. The Japanese equation for estimating GFR (eGFR) was recommended as a guideline for evaluating GFR in 2009 by The Japanese Society of Nephrology. However, benefits in the field of cancer chemotherapy with the use of eGFR have not yet been shown. To clarify the clinical benefits of eGFR, we investigated the renal function of 100 patients with gynecologic cancer who were treated with carboplatin from 2003 through 2009, and the carboplatin dosage was calculated by the Calvert formula in which eGFR was substituted for GFR. To predict the clinical benefit on the basis of carboplatin dosage using eGFR, we retrospectively divided the patients into two groups so that carboplatin dosage was within dosage in using eGFR and one was not. We compared response rates and adverse effects of the two groups. Renal function using eGFR was lower than renal function calculated by using the other formulae. Carboplatin dosage using eGFR was significantly lower than the dosage calculated with the other formulae (p<0.01). Moreover, the patients group actually, administered the dosage calculated by eGFR showed less side effects than the group of patients not treated this way, but the efficacy did not change. Thus, using eGFR in planning carboplatin dosage suggested clinical application to patients with Japanese gynecologic cancer.
authors.affiliation: Division of Pharmacotherapy, Kinki University School of Pharmacy, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kidera
authors.forename: Masahiko
authors.initials: M
authors.lastname: Nakao
authors.forename: Masanobu
authors.initials: M
authors.lastname: Tsubaki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yoshinaga
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Kajitani
authors.forename: Masashi
authors.initials: M
authors.lastname: Yanae
authors.forename: Mika
authors.initials: M
authors.lastname: Sakano
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Yamazoe
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Chiba
authors.forename: Kenzo
authors.initials: K
authors.lastname: Moriyama
authors.forename: Shozo
authors.initials: S
authors.lastname: Nishida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D044466:Asian People; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin